About the Company
We do not have any company description for Kalaris Therapeutics, Inc. at the moment.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on Kalaris Therapeutics, Inc.
Kalaris Reports Second Quarter 2025 Financial Results and Provides Business Updates
Continuing to enroll nAMD patients in a Phase 1 trial of TH103, a novel, differentiated anti-VEGF agent engineered to potentially provide longer-lasting and increased anti-VEGF activity to treat ...
Kalaris Therapeutics, Inc.: Kalaris Announces Closing of Merger with ...
The combined company will operate under the name Kalaris Therapeutics, Inc. and its shares are expected to begin trading on The Nasdaq Global Market on March 19, 2025 under the ticker symbol "KLRS." ...
Kalaris Therapeutics Elects New Directors at Annual Meeting
Detailed price information for Kalaris Therapeutics Inc (KLRS-Q) from The Globe and Mail including charting and trades.
Kalaris Therapeutics, Inc. (KLRS) - Yahoo Finance
PALO ALTO, Calif., May 23, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and ...
Kalaris Therapeutics, Inc. (KLRS) latest stock news and headlines ...
Kalaris to Present at Noble Capital Markets 2025 Emerging Growth Equity Conference PALO ALTO, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a ...
Kalaris Therapeutics Inc News (KLRS) - Investing.com
Kalaris Therapeutics, Inc. (NASDAQ:KLRS), a biopharmaceutical company with a market capitalization of $125 million, announced new ...
Kalaris Therapeutics, Inc. Common Stock (KLRS) SEC Filings
Mar 23, 2025 Nasdaq Listed Market: Closed Kalaris Therapeutics, Inc. Common Stock (KLRS) Volume: 40,759 52 Week Range: 7.96 - 24.15 ...
AlloVir and Kalaris Therapeutics Announce Agreement for ...
--AlloVir, Inc. today announced that it has entered into a definitive merger agreement to combine with Kalaris Therapeutics in an all-stock transaction. Under the terms of the agreement, AlloVir ...
Kalaris Therapeutics appoints new board chair By Investing.com
Kalaris Therapeutics appoints new board chairIn other recent news, AlloVir, Inc. has announced a merger with Kalaris Therapeutics, Inc., following shareholder approval. The merger is expected to close ...
Kalaris Therapeutics Inc. (KLRS) Stock Price Today - WSJ
View the latest Kalaris Therapeutics Inc. (KLRS) stock price, news, historical charts, analyst ratings and financial information from WSJ.
Kalaris Therapeutics, Inc.: Kalaris Reports Second Quarter 2025 Financial Results and Provides Business Updates
Continuing to enroll nAMD patients in a Phase 1 trial of TH103, a novel, differentiated anti-VEGF agent engineered to potentially provide longer-lasting and increased anti-VEGF activity to treat neova ...
About Kalaris Therapeutics Inc (KLRS) - Investing.com
Get an in-depth profile of Kalaris Therapeutics Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information. As of ...
Similar Companies
Loading the latest forecasts...